Comparing Skyrizi vs Yuflyma
| Skyrizi (risankizumab) | Yuflyma (adalimumab) |
|
|---|
| Skyrizi (risankizumab) | Yuflyma (adalimumab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease, Crohn's Disease - Active, Crohn's Disease - Maintenance, Hidradenitis Suppurativa, Plaque Psoriasis, Polyarticular Juvenile Idiopathic... View more |
Related suggestions Ulcerative Colitis
Popular comparisons
|
|||||||
| More about Skyrizi (risankizumab) | More about Yuflyma (adalimumab) | ||||||||
| Ratings & Reviews | |||||||||
|
Skyrizi has an average rating of 8.1 out of 10 from a total of 67 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 12% reported a negative effect. |
Yuflyma has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Skyrizi side effects |
View all Yuflyma side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Skyrizi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yusimry View more | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
672 hours |
480 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 194 drugs are known to interact with Skyrizi:
|
A total of 560 drugs are known to interact with Yuflyma:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
April 23, 2019 |
May 23, 2023 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.